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Abstract
Introduction: We aimed to enumerate the rate of pelvic recurrence
following radical cystectomy at university-affiliated hospitals in
Canada.
Methods: Canadian, university-affiliated hospitals were invited to
participate. They were asked to identify the first 10 consecutive
patients undergoing radical cystectomy starting January 1, 2005,
who had urothelial carcinoma stages pT3/T4 N0-2 M0. The first 10
consecutive cases starting January 1, 2005 who met these criteria
were the patients submitted by that institution with information
regarding tumour stage, age, number of nodes removed, and last
known clinical status in regard to recurrence and patterns of failure.
Results: Of the 111 patients, 80% had pT3 and 20% pT4 disease,
with 62% being node-negative, 14% pN1, and 27% pN2; 57%
had 10 or more nodes removed. Cumulative incidence of pelvic
relapse was 40% among the entire group
Conclusions: This review demonstrates a high rate of pelvic tumour
recurrence following radical cystectomy for pT3/T4 urothelial cancer.

Introduction
The current gold standard management for locally advanced
urothelial bladder cancer consists of neoadjuvant chemotherapy, followed by radical cystectomy with pelvic node
dissection and neo-bladder reconstruction, as appropriate.1,2 This combination addresses the loco-regional pelvic
90

disease and the systemic micrometastatic tumour burden.
Unfortunately, cure rates have remained static for over two
decades, reflecting the lack of more effective systemic treatment and a continuing problem with pelvic tumour eradication.3 We report the results of a Canadian academic centre
survey designed to enumerate the proportion of patients
developing pelvic tumour recurrence following contemporary cystectomy.

Methods
In 2011, 17 university-affiliated cancer clinics across Canada
were invited to participate in this effort. Specifically, each
centre was asked to identify a trio of investigators comprised
of a pathologist, urologist, and radiation oncologist. Following
ethics approval, the pathologist generated a chronologically
accurate list of consecutive patients undergoing cystectomy
for bladder cancer starting January 1, 2005. To be eligible
for the study, the following criteria had to be met: 1) primary
urothelial carcinoma with or without any admixed other
histologies (no other primary histologies such as squamous,
adenocarcinoma, or small cell were included); 2) no known
hematogenous metastases or nodal involvement above the
iliac bifurcation; 3) surgery performed with curative intent
and no gross residual disease; 4) neoadjuvant or adjuvant
chemotherapy was permitted; 5) only pT3/T4 N0-2 stages.
The first 10 consecutive cases meeting these criteria, regardless of whether the subsequent clinical outcome was fully
known or not, constituted the required patient sample from
each institution. It was the expectation that this method
of case selection from each hospital’s surgical pathology
chronological record would minimize case selection bias.
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Abstracted clinical data included birthdate, date of radical
cystectomy, pathological stage, number of removed lymph
nodes recorded in the pathology report, date of last clinical
contact, and last known clinical status. Defining any hematogenous spread or nodal disease above or at L5 as distant
metastases (DM) and any pelvic soft tissue or nodal disease
below L5 as pelvic recurrence (PR), the eventual clinical
status was categorized as: 1) no tumour recurrence; 2) pelvic
recurrence only (with date); 3) distant metastases only (with
date); 4) distant metastases and pelvic recurrence regardless
of whether identified simultaneously or not; and 5) pelvic
tumour status unknown. The anonymized individual patient
data sheets were collated centrally for compilation and analysis. Arithmetic proportions of patients developing pelvic
recurrence with or without distant metastases were tabulated
and cumulative incidence calculations were performed to
compute the risk of developing pelvic relapse.

Results
Eleven university-affiliated cancer clinics (Vancouver,
Edmonton, London, Kingston, Ottawa, Princess Margaret,
Sunnybrook, McGill, CHUM, Saint John, and Sudbury) from
five provinces participated.
Ten centres from five provinces provided data on 111
patients (Table 1). Age ranged from 43.9–92.7 years, (mean/
median 69.6/70.9 years). T stage was pT3 in 81 patients
Table 1. Patient characteristics and recurrence status
Characteristics
Age
<65
≥65
Unknown
Node status
pN0
pN1
pN2
Unknown
Pathologic stage at cystectomy
pT3a
pT3b
pT3NOS
pT4a
pT4b
pT4NOS
Nodes removed
<10
≥10
Unknown
Recurrence status at followup
None
Pelvic only
Distant only
Pelvic and distant
Unknown

N (%)
31 (27.9)
79 (71.2)
1 (0.9)
62 (55.9)
14 (12.6)
27 (24.3)
8 (7.2)
39 (35.1)
41 (37.0)
1 (0.9)
27 (24.3)
2 (1.8)
1 (0.9)
52 (46.9)
57 (51.4)
2 (1.8)
36 (32.4)
13 (11.7)
22 (19.8)
25 (22.5)
15 (13.5)

(pT3a=39, pT3b=41, pT3NOS=1) and pT4 in 30 (pT4a=27,
pT4b=2, pT4NOS=1). N stage was N0 in 62 patients, N1 in
14, N2 in 27, and Nx in 8. The median number of nodes dissected was 11 and ranged from 0–67. With regard to nodes,
26.6% had more than 15 nodes resected; 21.1% had 11–15
resected; 26.6% had 6–10 resected; 22.9% had 5 or less
resected. Median time to last followup was 15 months, and
ranged from 0–87 months. PR occurred in 34.2% of patients;
51.4% had no PR. Pelvic status was unknown in 14.4%, but
these were considered as having no PR. Of the 38 patients
with PR, 25 (65.8%) developed DM and 13 (34.2%) had
only PR. Fig. 1 shows the 40% pelvic recurrence rate when
calculated as cumulative incidence.

Discussion
Starting with Whitmores’ emphasis on the nodal dissection
component of a radical cystectomy in 19624 to examination of planned perioperative adjuvant radiotherapy in the
70s and 80s, Skinners’ compilation of the large, singleinstitutional testament to comprehensive, meticulous surgical technique through the 90s,5 and calibrated further by
Herrs’ elucidation of the importance of resected node counts
in 2003,6 these strategies have addressed the all-important
matter of pelvic tumour eradication in bladder cancer. In a
2007 comprehensive review, Cagiannos et al tabulated contemporary post-cystectomy pelvic recurrence rates ranging
from 3.9‒29%.7 These numbers have significantly underestimated the actual occurrence of loco-regional failures due
to: 1) dilution by reporting overall rather than per T stage
recurrence rates; 2) calculation of simple proportions rather
than cumulative incidence risk; 3) requirement of biopsy
confirmation; 4) discounting pelvic failure if accompanied
or preceded by systemic metastases; and 5) relative inattention to pelvic imaging following the development of distant
disease. These detriments to accurate risk determination are
compounded by the known insensitivity of pelvic imaging
in the context of subcentimetric tumour deposits.
Two experiences published in 2005 and 2012 define
the scope of this ongoing pelvic control issue. The SWOG
trial of neoadjuvant chemotherapy featured a 32% biopsyproven crude simple pelvic relapse rate in T3/T4 patients.8
The MRC trialists’ report of the long-term results of the
seminal European neoadjuvant chemotherapy trial yielded a 49% loco-regional relapse rate.9 While documenting
the high intrapelvic recurrence rates, both these trials also
demonstrate that although overall survival is improved by
5%, neoadjuvant chemotherapy does not have a discernible
impact on pelvic tumour control.
The 40% pelvic relapse rate in this cross-Canada
study is in concert with the experiences detailed above.
Unfortunately, it is likely that even this high risk is an underestimate, given that we used the conservative assumption
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Month
At risk (events)

0
110 (25)

12
46 (10)

24
27 (3)

36
19 (0)

Fig. 2. Cumulative incidence of pelvic recurrence following cystectomy of 110
patients; subgroups defined by nodal status at time of surgery.

that patients in whom pelvic tumour status was unknown
were free of tumour.
The strength of our data is two-fold. Firstly, the data is
a random snapshot of outcomes. By virtue of the patient
retrieval strategy used, the selection biases that can occur
when measuring outcomes in patients selected for participation in a clinical trial or abstracting data from cultivated
institutional patient data sets is reduced. Secondly, and likely
most importantly, the sole and simple object of this exercise was to enumerate pelvic relapse in unselected patients
undergoing contemporary surgery at widely dispersed aca-

demic institutions. This is in contrast to the general literature,
wherein pelvic control is not the prime focus of published
reports.
Weaknesses of this data set are the relatively small number of cases audited at each centre (10), the limited rigour
in determining pelvic tumour status in those patients for
whom it was deemed “unknown” from the readily available
documentation, and omission of surgical margin status. The
latter two are a reflection of the practicalities of a multicentre
survey.
Whereas enumeration defines the magnitude of the
problem, understanding causation requires unraveling the
interplay between the culprit clinical, surgical, and pathological factors. In this Canadian patient cohort, node positivity predicted for higher PR (Fig. 2), while the number of
lymph nodes resected appeared to not materially influence

Fig. 3. Cumulative incidence of pelvic recurrence following cystectomy of 110
patients; subgroups defined by number of nodes removed.

Fig. 4. Cumulative incidence of pelvic recurrence following cystectomy of 110
patients; subgroups defined by pathological tumour stage.

Fig. 1. Cumulative incidence of pelvic recurrence following cystectomy of 110
patients; number of patients at risk and events occurring per 12-month period
at bottom of graph.
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PR (Figs. 3 and 4). This latter observation is at odds with
what currently comprises a cardinal aspect of radical cystectomy, whereby still more extensive nodal clearance is
being advocated and investigated.10,11 Lymph node counts,
be they absolute or proportional, are vulnerable to variations in retrieval from the resected specimen. Additionally,
the relatively small number of patients and the possibility
that patients with node-positive disease are more likely to
manifest metastatic disease, thus reducing the clinical probability of identifying PR, likely explain this anomalous result.
Our data must not be misconstrued as minimizing the
importance of adequate nodal dissection. Christodouleas
has validated, extramurally, the robustness of assigning
post-cystectomy patients to low-, intermediate- and highrisk categories on the basis of pathological stage, numbers
of resected lymph nodes, and margin status.12 The soundness
of this model has been further corroborated by Froehner13
and Ku14 This stratification of PR risk accounts for tumourrelated parameters. Other factors can be considered as being
patient- or treatment-related. Given that, by definition, all
patients undergoing curative radical cystectomy had to be
sufficiently well-suited in terms of medical condition and
performance status to undergo the surgery, it is unlikely that
other patient variables have contributed to the probability
of PR. Treatment factors include the use of neo or adjuvant
chemotherapy, thoroughness of the operation, and case volume issues that speak to the surgical team’s experience. As
noted previously, randomized trial data show that administering chemotherapy to these patients does not reduce PR
rates. While nodal status is unequivocally a tumour parameter, resected nodal counts definitely and margin status
possibly also reflect surgical rigor. That all these patients
underwent surgery at academic hospitals with cancer clinic
affiliations speaks to the likely sufficient patient volumes and
requisite surgical expertise.
In the final analysis, this high rate of PR cannot be attributed to any unfortunate case mix or singular compromise
of accepted bounds of contemporary surgical management.
Rather, it is almost certainly a reflection of the true rates of
pelvic failure revealed when the singular focus of the study
is the number of pelvic relapses.
The approach of discounting pelvic recurrence if it
coincides with or succeeds distant metastases speaks to a
perspective that relegates loco-regional failure to the status
of being an unfortunate, but clinically unimportant event.
This derives from the fact that the majority of patients with
pelvic relapse also develop distant disease. However, it
remains the clinical reality that: 1) essentially, no patient
with pelvic failure can be salvaged, rendering the magnitude
of the pelvic relapse problem an absolute ceiling on surgical
curability; 2) in the 15% minority of patients who develop
isolated pelvic relapse, the clinical outcome is determined
by local and not distant disease; and 3) patients with recur-

rent tumour in the pelvis can and do experience significant
morbidity that is poorly palliated, whether or not distant
disease coexists.
This study was undertaken because of the clinical perception that PR remains a significant problem following curative
surgery in pT3/T4 urothelial bladder cancer, an issue that is
not readily discernible in the uro-oncological literature. The
multi-institutional data presented corroborates this materially high risk of loco-regional failure following contemporary radical cystectomy in advanced-stage presentation and
emphasizes the need to address the issue definitively. Pelvic
control is a necessary, but insufficient requirement for cure.
Giving it the focus it warrants will enable uro-oncologists to
elucidate the optimal, nuanced amalgam of surgery, radiotherapy, and systemic therapies that maximizes the cure
potential for the individual bladder cancer patient.
In North America, the NRG clinical trials group15 has
opened a randomized trial examining adjuvant radiotherapy and similar studies are being launched in France, Asia,
and the U.K. This is the currency of clinical investigation
into the treatment of all other solid malignancies that has
yielded ever-improving local, regional, and systemic control,
a scenario that can be realistically anticipated for bladder
cancer as well.
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